Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Return on Assets (2016 - 2025)

Historic Return on Assets for Celldex Therapeutics (CLDX) over the last 15 years, with Q3 2025 value amounting to 0.33%.

  • Celldex Therapeutics' Return on Assets fell 1500.0% to 0.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.33%, marking a year-over-year decrease of 1500.0%. This contributed to the annual value of 0.25% for FY2024, which is 900.0% up from last year.
  • According to the latest figures from Q3 2025, Celldex Therapeutics' Return on Assets is 0.33%, which was down 1500.0% from 0.28% recorded in Q2 2025.
  • Celldex Therapeutics' 5-year Return on Assets high stood at 0.16% for Q4 2021, and its period low was 0.43% during Q3 2023.
  • Its 5-year average for Return on Assets is 0.27%, with a median of 0.27% in 2022.
  • As far as peak fluctuations go, Celldex Therapeutics' Return on Assets tumbled by -1700bps in 2023, and later skyrocketed by 2500bps in 2024.
  • Celldex Therapeutics' Return on Assets (Quarter) stood at 0.16% in 2021, then crashed by -100bps to 0.31% in 2022, then dropped by -22bps to 0.38% in 2023, then surged by 48bps to 0.2% in 2024, then crashed by -71bps to 0.33% in 2025.
  • Its Return on Assets stands at 0.33% for Q3 2025, versus 0.28% for Q2 2025 and 0.23% for Q1 2025.